Introduction {#Sec1}
============

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are rare small-vessel vasculitides that are characterized by the presence of circulating anti-neutrophil cytoplasmic autoantibodies (ANCAs) in 80--94 % of affected patients \[[@CR1], [@CR2]\]. The prevalence of ANCA-associated vasculitis (AAV) has increased in recent years, in part due to increased recognition of these complex diseases. AAVs have an annual incidence of 20 per million population \[[@CR3]\]. Renal involvement is present in \>50 % of patients at presentation and develops in 70--80 % during the course of the disease. The typical histopathology is a focal segmental and necrotizing crescentic glomerulonephritis (GN) with minimal immunoglobulin deposition in vessel walls \[[@CR4]\]. GPA and MPA account for 80 % of cases of rapidly progressive GN \[[@CR5]\]. Progression to end-stage renal disease (ESRD) can be prevented by prompt diagnosis and timely initiation of therapy.

GPA and MPA are severe, progressive diseases that, left untreated, can lead to death from multisystem organ failure. The introduction of therapy with glucocorticoids combined with cyclophosphamide improved the prognosis for AAV \[[@CR6]\]. However, not all patients respond to cyclophosphamide, and \>50 % of responders suffer a relapse within 3--5 years \[[@CR7]\]. Disease recurrence and drug-related toxicity continue to produce significant morbidity and mortality, and remain the main challenges in patient management \[[@CR8]\]. In a recent analysis of four European clinical trials involving 524 AAV patients, the greatest impact on patients in the first year of therapy was from adverse events (AEs) rather than active vasculitis \[[@CR9]\]. In this analysis, the burden of AEs was quantified using a severity score for leukopenia, infection, and other AEs with additional weighting for follow-up duration. The burden of AEs was predicted by the severity of renal impairment and advanced age.

ANCAs are implicated in the pathogenesis of GPA and MPA \[[@CR10]\]. Consequently, therapies targeting the cells that produce these antibodies (short-lived plasma cells of B-cell origin) and other functions of B cells, such as antigen presentation and cytokine release, have been considered as potential treatments for AAV. After promising initial data from smaller studies, two randomized clinical trials have shown that rituximab, an anti-CD20 monoclonal antibody that targets B cells, is not inferior to cyclophosphamide for induction of remission in severe GPA and MPA \[[@CR11], [@CR12]\]. Consequently, in April 2011 the US FDA approved rituximab for the treatment of these diseases, heralding a new era in disease management. The aim of this review is to examine the latest evidence supporting the use of rituximab in GPA/MPA within the context of other available treatment approaches.

Current treatment options {#Sec2}
=========================

The European Vasculitis Study Group (EUVAS) classifies AAV according to particular subtypes in order to assign different treatment regimens (Table [1](#Tab1){ref-type="table"}) \[[@CR13]\]. Therapy consists of a staged treatment approach involving two treatment phases: remission-induction and remission-maintenance.Table 1EUVAS disease categorization for GPA/MPA and treatment recommendations for induction and maintenance of remission \[[@CR13]\]EUVAS disease subtypeDefinitionInductionMaintenanceLocalizedUpper and/or lower respiratory tract disease without other systemic involvement or constitutional symptomsMethotrexate + steroidsLow-dose steroids + azathioprine or methotrexateEarly systemicWithout organ-threatening or life-threatening diseaseMethotrexate or cyclophosphamide + steroidsLow-dose steroids + azathioprine or methotrexateGeneralizedRenal or other life-threatening disease; serum creatinine \<500 μmol/lCyclophosphamide or rituximab^a^ (or mycophenolate mofetil) + steroidsLow-dose steroids + azathioprineSevereRenal or other vital organ failure; serum creatinine \>500 μmol/lCyclophosphamide or rituximab^a^ + steroids + plasma exchangeLow-dose steroids + azathioprineRefractoryProgressive disease unresponsive to cyclophosphamide and glucocorticoidsRituximab, mycophenolate mofetil, intravenous immunoglobulin, anti-thymocyte globulin, 15-deoxyspergualin, alemtuzumab, hematopoietic stem cell transplantation--^a^Rituximab can be recommended for newly diagnosed, relapsing, and refractory disease

Standard of care {#Sec3}
----------------

Combination therapy with corticosteroids and cyclophosphamide was established as standard therapy after the seminal paper published by Fauci et al. \[[@CR6]\]. Prolonged courses of cyclophosphamide are effective for the treatment of AAV, with 91 % of patients showing improvement in disease status and 75 % achieving sustained disease remission. However, the cost of achieving remission using this extended cyclophosphamide dosing regimen was substantial: 46 % of patients developed a serious infection, 57 % became infertile, and 43 % developed hemorrhagic cystitis. In addition, there was a 33-fold increased risk of bladder carcinoma and an 11-fold increased risk of lymphoma. Overall, 42 % of patients developed some form of serious morbidity directly attributable to therapy when cyclophosphamide was used for 2 years according to the NIH regimen. Modern treatment strategies have focused on minimizing cyclophosphamide exposure or eliminating its use altogether. Pulsed cyclophosphamide administration has been considered as a less toxic alternative to daily cyclophosphamide \[[@CR14], [@CR15]\]. Both pulsed cyclophosphamide \[15 mg/kg intravenously (IV) every 2--3 weeks\] and daily cyclophosphamide (2 mg/kg/day) produce similar remission rates, although long-term follow-up of patients enrolled in the CYCLOPS trial indicates that the risk of relapse continues to increase among patients treated with pulsed cyclophosphamide \[[@CR16]\]. Between 10 and 40 % of patients fail to achieve sustained remission with standard induction therapy through inefficacy, severe AEs, or intolerance \[[@CR14]--[@CR16]\].

For remission-maintenance, the CYCAZAREM trial showed that cyclophosphamide could be replaced with azathioprine after remission without increasing the rate of relapse \[[@CR17]\]. Azathioprine and low-dose steroid tapered to ≤10 mg/day are recommended to reduce exposure to cyclophosphamide and steroids, although relapses occur in \>50 % of patients by 7 years \[[@CR13], [@CR17], [@CR18]\]. The IMPROVE trial tested the use of mycophenolate mofetil (MMF) as a remission-maintenance agent in 156 patients with AAV \[[@CR19]\]. The rate of relapse with MMF 2,000 mg daily with dose further reduced at 12 months to 1,500 mg daily and at 18 months to 1,000 mg daily was almost double that observed with azathioprine 2 mg/kg/day \[adjusted hazard ratio for relapse associated with MMF, 1.80 (95 % confidence interval 1.10--2.93); *P* = 0.02\], indicating that MMF at the dose used is not as effective as azathioprine for maintaining disease remission. Methotrexate is another alternative as a remission-maintenance agent \[[@CR20]\].

Alternatives to standard of care {#Sec4}
--------------------------------

Standard of care for remission-induction may not be sufficient or appropriate for all patients with GPA/MPA. Methotrexate can be used as an alternative to cyclophosphamide in patients without renal involvement or with only mild renal involvement (early systemic disease) \[[@CR21]\]. Long-term observation, however, shows that induction treatment with methotrexate results in less effective disease control than cyclophosphamide-based induction therapy \[[@CR22]\]. MMF is an alternative to cyclophosphamide for remission-induction in patients with mild to moderate renal disease \[[@CR23]\]. A randomized, non-inferiority trial (MYCYC) compared remission-induction with MMF or cyclophosphamide in newly diagnosed GPA/MPA. The study did not reach its primary endpoint of demonstrating that MMF is non-inferior to cyclophosphamide in terms of remission-induction when steroids were used according to protocol, although non-inferiority was shown for remission-induction irrespective of steroid compliance \[[@CR24]\].

For patients with severe (life-threatening) AAV, adjunctive plasma exchange may be considered. MEPEX was a randomized, controlled trial comparing IV methylprednisolone or plasma exchange with cyclophosphamide and oral prednisolone in severe renal vasculitis, with renal recovery as the primary outcome measure \[[@CR25]\]. At 3 months, a significantly greater proportion of patients who received plasma exchange were alive and independent of dialysis compared with those who received IV methylprednisolone (69 versus 49 %, *P* = 0.02), thus supporting the use of plasma exchange in the treatment of AAV with renal failure. The use of adjunctive plasma exchange with standard immunosuppressive therapy and glucocorticoids in less severe renal disease is being investigated in PEXIVAS, a large international multicenter trial.

Rituximab {#Sec5}
=========

Rationale for B-cell-targeted therapy {#Sec6}
-------------------------------------

Rituximab was first FDA approved in 1997 for the treatment of non-Hodgkin lymphoma. It is also licensed in rheumatoid arthritis (RA) for treating patients with an inadequate response to tumor necrosis factor-α inhibitors. Rituximab has also been studied in patients with glomerular diseases, including lupus nephritis, membranous nephropathy, and focal glomerulosclerosis \[[@CR26]--[@CR29]\]. The rationale for using rituximab in GPA/MPA stems from the central role played by B cells in the pathogenesis of these diseases and evidence for the pathogenicity of circulating ANCAs \[[@CR30]\]. B cells are the precursors of short-lived plasma cells, which are thought to be the primary source of autoantibodies, including ANCAs. B cells may contribute to other aspects of the pathogenesis of GPA and MPA, including co-stimulation, cytokine production, and antigen presentation \[[@CR30]\]. The action of cyclophosphamide also points to a role for B cells, as it may exert some of its activity in GPA/MPA through the suppression of B-cell function \[[@CR31]\].

Rituximab for remission-induction in GPA/MPA {#Sec7}
--------------------------------------------

Patients with GPA/MPA have experienced remission rates of approximately 90 % with rituximab in open-label clinical trials and case series \[[@CR32]--[@CR34]\]. However, these studies were neither randomized nor controlled, and criteria for remission were not rigidly applied. Two recent randomized controlled trials (RAVE and RITUXVAS) investigated the efficacy and safety of rituximab in GPA/MPA. The US FDA approval of rituximab was based on data from the RAVE study \[[@CR11]\]. RAVE enrolled 197 patients with severe GPA/MPA, approximately 50 % of whom had newly diagnosed disease and 50 % had severe relapsing disease at diagnosis. Patients with severe renal impairment (serum creatinine \>4 mg/dl) and those requiring intubation for alveolar hemorrhage were excluded. However, 66 % of each group had renal disease at baseline, and lung involvement was present in a little over half of each group with pulmonary hemorrhage in approximately one quarter of each group.

This was a double-blind, double-dummy, controlled, randomized trial with preset primary, secondary, and tertiary endpoints. Patients were randomized to receive either rituximab (375 mg/m^2^ once weekly for 4 weeks) or oral cyclophosphamide (2 mg/kg/day) for a maximum of 6 months (remission-induction period). All patients received the same glucocorticoid regimen (1--3 pulses of IV methylprednisolone 1,000 mg, followed by oral prednisone 1 mg/kg tapered over 5 months). On achieving remission at 3--6 months, patients in the cyclophosphamide arm were switched to a remission-maintenance regimen of azathioprine 2 mg/kg/day. Patients in the rituximab group who achieved remission during the same period were maintained on placebo rather than azathioprine after initial rituximab except for a tapering corticosteroid dose similar to the cyclophosphamide group, They thus received no active treatment after 5 months, when their prednisone was discontinued. Patients were followed for at least 18 months to gauge long-term responses and the effect of rituximab on immune tolerance. The primary endpoint was achievement of complete remission, as defined by a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) \[[@CR35]\] of zero and no prednisone by 6 months.

At 6 months, 64 % of rituximab-treated patients achieved the primary endpoint versus 53 % in the cyclophosphamide group, a result that met the criterion for non-inferiority (*P* \< 0.001). In patients with relapsing disease at baseline, 67 % (34/51) of patients in the rituximab group and 42 % (21/50) of patients in the cyclophosphamide group achieved complete remission (*P* = 0.01). A secondary endpoint was remission defined as BVAS/WG of 0 and prednisone ≤10 mg/day; this endpoint was achieved by 71 % of rituximab- and 62 % of cyclophosphamide-treated patients. Results from the long-term follow-up of the RAVE trial showed 48 and 39 % of patients in the rituximab arm were in sustained remission at 12 and 18 months compared to 39 and 33 % of patients in the CYC arm, demonstrating that remission-induction with rituximab without any maintenance therapy was non-inferior to CYC followed by azathioprine \[[@CR36]\].

Approximately half of the patients in RAVE had major renal disease at baseline (Box 1). Although baseline mean estimated glomerular filtration rate (e-GFR) was significantly worse in the rituximab group (creatinine clearance 53 versus 69 ml/min; *P* = 0.01), the proportion of renal patients achieving the study primary endpoint was not significantly different between the two groups (rituximab 61 % versus cyclophosphamide 63 %; *P* = 0.92) \[[@CR37]\]. There was no difference in the proportion of patients with sustained remission at 18 months (rituximab 42 % versus cyclophosphamide 43 %; *P* = 0.84). Mean e-GFR also increased in parallel in both groups. There was no overall difference in the incidence of renal flares between groups; however, MPA patients treated with rituximab were more likely to experience renal flares than those treated with cyclophosphamide/azathioprine (4 MPA patients treated with rituximab had a total of 5 renal flares by month 18 versus none treated with cyclophosphamide/azathioprine; *P* = 0.04).

Box 1: Definition of major renal disease in the RAVE study \[[@CR11]\]

The safety data from RAVE showed no significant differences between the treatment groups in the incidence of AEs, serious AEs, or non-disease-related AEs \[[@CR11]\]. There were more infusion reactions with rituximab (but only during the initial infusion---12 vs. 7 %) and serious infections (sepsis and pneumonia) were found in about 10 % of either group. Two patients in each treatment group died. No additional safety issues were detected in patients followed for ≥18 months \[[@CR38]\], including no difference in new malignancies between the groups (6 and 2 cases in the rituximab and cyclophosphamide groups, respectively; further details are available in Stone et al. \[[@CR11]\]).

RITUXVAS was a multicenter open-label study that recruited patients with newly diagnosed AAV and renal involvement (severe GPA/MPA) \[[@CR12]\]. Patients enrolled in RITUXVAS were older (median age 68 years) than the patients in the RAVE cohort (mean age 51--54 years) and had worse renal function at baseline (median GFR 12--20 ml/min in RITUXVAS and mean GFR 54--69 ml/min in RAVE). Study participants were randomized to treatment with rituximab (375 mg/m^2^ once weekly for 4 weeks) plus two IV cyclophosphamide pulses, or IV cyclophosphamide for 3--6 months (control group). For remission-maintenance, the control group received oral azathioprine for up to 12 months. This trial included patients who had severe renal disease, with 9/44 patients requiring dialysis at trial entry. All patients received the same glucocorticoid regimen of IV methylprednisolone 1,000 mg, followed by oral prednisolone 1 mg/kg/day, tapered to 5 mg/day by 6 months. Rates of sustained remission (over 12 months) were high in both treatment groups, although they did not differ significantly: rituximab/cyclophosphamide 76 % (25/33) and cyclophosphamide 82 % (9/11) (*P* = 0.68). Mortality in this older, renal-impaired group was high (18 %) in both treatment groups, although the incidence of serious AEs and infections was similar in the two treatment groups.

Rituximab for remission-induction in refractory GPA/MPA {#Sec9}
-------------------------------------------------------

EUVAS defines refractory disease as progressive disease unresponsive to cyclophosphamide and corticosteroids \[[@CR13]\]. Among GPA/MPA patients receiving standard therapy of cyclophosphamide and glucocorticoids, up to 5 % are refractory to treatment (see Table [1](#Tab1){ref-type="table"}) \[[@CR39]\]. The first use of rituximab to treat refractory vasculitis was described in 2001 \[[@CR40]\]. Other groups have since shown that rituximab is effective at inducing remission in GPA/MPA patients with refractory disease \[[@CR41]--[@CR43]\]. In one multicenter series involving 65 patients with refractory disease, complete remission was achieved in 75 % of patients treated with rituximab \[[@CR44]\].

Glucocorticoid taper {#Sec10}
--------------------

As high-dose glucocorticoid treatment is associated with considerable toxicity, implementing measures to reduce glucocorticoid exposure without increasing the risk of relapse is critical. Current remission-induction regimens include high-dose glucocorticoids, which are then tapered when remission is achieved \[[@CR13]\]. The relationship between glucocorticoid dose and its immunosuppressive and anti-inflammatory actions is complex \[[@CR45]\].

When combined with cytotoxic medications, high-dose glucocorticoids may increase treatment-related toxicity. Infections in GPA/MPA are most common in the first 2 months of treatment when glucocorticoid doses are highest. Although this relationship is confounded by disease activity and co-treatment with cytotoxic therapy, it is important to note that infection rates fall in parallel with decreasing glucocorticoid dose despite the maintenance of cytotoxic agents. Glucocorticoid dose-dependent increases in infections have been observed in RA \[[@CR46]\]. Furthermore, high cumulative doses of glucocorticoids are associated with other comorbidities, including osteoporosis, cardiovascular disease, and gastrointestinal bleeding \[[@CR47]\]. Despite the evidence for an association between higher glucocorticoid doses and AEs, there is a paucity of evidence to guide the optimal glucocorticoid dosing in GPA/MPA.

Results from RAVE and RITUXVAS indicate that glucocorticoid tapering can be achieved during remission-induction with either rituximab or cyclophosphamide. In RAVE, patients received 1--3 pulses of IV methylprednisolone (1,000 mg each), followed by oral prednisone (1 mg/kg/day) with dose tapering, such that by 5 months all patients in remission without disease flare had discontinued glucocorticoids completely \[[@CR11]\]. The glucocorticoid taper occurred later in RITUXVAS: the prednisolone dose was 5 mg/day at 6 months \[[@CR12]\]. By 12 months, the median weight-adjusted doses of prednisolone were still approximately 5 mg daily (0.071 and 0.082 mg/kg/day) in the rituximab and control groups, respectively. Another uncontrolled study in patients with renal AAV, involving induction therapy with low-dose cyclophosphamide plus rituximab followed by azathioprine maintenance, employed a low-dose glucocorticoid regimen with withdrawal at 3 months \[[@CR48]\]. This strategy proved effective, with a relapse rate of only 13 % over 18 months and an acceptable safety profile. The PEXIVAS trial is designed to determine the non-inferiority of a reduced-dose glucocorticoid regimen compared with standard-dose glucocorticoids in reducing death and ESRD.

If the decision is made to use a remission-maintenance regimen in AAV, low-dose glucocorticoids are often used in combination with azathioprine or methotrexate. The optimal dose and duration of glucocorticoid therapy in relapse prevention have not been established. The efficacy of long-term, low-dose glucocorticoids to prevent relapses is controversial and must be balanced with the risk of AEs due to toxicity from high cumulative doses of glucocorticoids. A systematic review and meta-analysis of 13 studies (*n* = 983) concluded that longer courses of glucocorticoids were associated with fewer relapses and that low-dose glucocorticoids for \>12 months would be anticipated to provide benefits for patients \[[@CR18]\]. In contrast, a cohort study that evaluated the effect of glucocorticoid therapy on patient outcomes and AEs reported that therapy beyond 6 months was associated with a significantly greater risk of infections but no significant reduction in the rate of relapse \[[@CR49]\].

Rituximab as maintenance immunosuppressive therapy in GPA/MPA {#Sec11}
-------------------------------------------------------------

GPA and MPA are relapsing diseases, with approximately 50 % of patients following a chronic relapsing pattern, despite standard immunosuppression. Studies have shown that relapse may be more common in anti-proteinase 3-positive patients \[[@CR50], [@CR51]\]. The use of rituximab as maintenance therapy to prevent relapses in AAV has been evaluated in two open-label studies. In one study, 2-year fixed-interval re-treatment with rituximab was shown to lower relapse rate and maintain remission for a prolonged period compared with rituximab treatment at the time of flare \[[@CR52]\]. Administration of rituximab preemptively on the basis of B-cell repletion has also been shown to be effective in preventing relapses \[[@CR53]\]. Other open-label studies have confirmed the effectiveness of rituximab as a maintenance immunosuppressive agent \[[@CR54], [@CR55]\]. A recent retrospective analysis of 172 patients with ANCA vasculitis treated with scheduled rituximab dosing every 4 months demonstrated achievement of continuous B-cell depletion and long-term disease control \[[@CR56]\]. Controlled trials testing the effectiveness of rituximab as maintenance therapy are under way. Initial results from a prospective, randomized, controlled trial (MAINRITSAN) of patients with newly diagnosed (*n* = 91) or relapsing (*n* = 23) AAV who had achieved remission with standard therapy showed that rates of major relapse during maintenance therapy were lower among patients who received rituximab 500 mg every 6 months than among those receiving azathioprine (5.2 versus 25.4 %) \[[@CR57]\]. Another EUVAS randomized controlled trial (RITAZAREM) will investigate maintenance therapy with rituximab in patients with relapsing GPA/MPA. Patients in remission at 4 months following rituximab (4 × 375 mg/m^2^) will receive maintenance therapy with fixed-interval, repeat dosing with rituximab (1,000 mg every 4 months for 5 doses) or azathioprine \[[@CR58]\]. Patients will be followed after cessation of therapy to test the hypothesis that repeat-dose rituximab during remission induces lasting remission through depletion of auto-reactive memory B cells.

An emerging observation with repeated rituximab exposure has been the development of hypogammaglobulinemia, which may increase in frequency in patients who have previously been exposed to cyclophosphamide before rituximab treatment \[[@CR59]\]. In RAVE, a substantial proportion of GPA/MPA patients had low immunoglobulin levels at baseline, and low immunoglobulin levels were not associated with an increased risk of infection \[[@CR60]\]. Similarly, a single-center study reported that 21 % of patients had IgG levels below the lower limit of normal before rituximab treatment, with a trend toward lower levels after rituximab treatment over 2 years \[[@CR52]\]. As reported for the RAVE cohort, there was no clear association between hypogammaglobulinemia and infections.

For patients who have previously relapsed on maintenance therapies, such as azathioprine or MMF, continuing these agents after rituximab appears to have little benefit \[[@CR44]\]. Whether they reduce the risk of relapse after rituximab in treatment-naïve patients is not known.

In summary, available data indicate that once remission has been achieved, rituximab therapy using a fixed-interval re-treatment schedule is a potential alternative to azathioprine for remission-maintenance. The clinical importance of hypogammaglobulinemia with scheduled repeat doses of rituximab will be prospectively studied in ongoing and planned maintenance trials.

Rituximab in managing GPA/MPA patients with severe renal disease {#Sec12}
----------------------------------------------------------------

### Concomitant use of cyclophosphamide {#Sec13}

The time to remission (defined as absence of clinical disease activity and a BVAS score of zero) after a rituximab course has been around 2 months whether or not concomitant therapy with cyclophosphamide was used. The RITUXVAS trial enrolled older patients with more severe renal disease, with a median e-GFR of 20 ml/min, and included dialysis-dependent patients. Rituximab-treated patients received two doses of IV cyclophosphamide 15 mg/kg with the first course of rituximab \[[@CR12]\]. Remission occurred in 91 % of patients treated with rituximab, and at 12 months 76 % had sustained remission and a median e-GFR of 39 ml/min. However, in this older group with worse renal function at baseline, the mortality was 18 % in each group. A single-center prospective study of 23 ANCA-associated renal vasculitis patients with a median e-GFR of 24 ml/min also used a lower dose of cyclophosphamide (10 mg/kg) with the initial course of rituximab \[[@CR48]\]. Twenty-two of the 23 patients achieved remission and the median e-GFR was 42 ml/min by 6 months.

### Plasma exchange {#Sec14}

Plasma exchange is recommended as an adjunct to remission-induction therapy for selected patients with rapidly progressive severe renal disease in order to improve renal survival \[[@CR25]\]. It is also recommended for certain patients with severe pulmonary disease and pulmonary hemorrhage. An open-label, randomized, controlled study is under way (PEXIVAS; NCT01697267), which aims to clearly determine both the role of plasma exchange in severe AAV and whether glucocorticoid dosing can be safely reduced. PEXIVAS will randomize patients with severe AAV to one of four study groups: plasma exchange + standard-dose glucocorticoids; plasma exchange + reduced-dose glucocorticoids; no plasma exchange + standard-dose glucocorticoids; or no plasma exchange + reduced-dose glucocorticoids. Although induction therapy will in most cases involve standard cyclophosphamide/high-dose glucocorticoids, rituximab is a permitted alternative for suitable patients. In such cases, rituximab should be dosed after the plasma exchange because of the potential for rituximab to be removed by plasma exchange.

Unique populations {#Sec15}
------------------

### Transplantation {#Sec16}

In patients with ESRD, kidney transplantation improves survival compared with maintenance dialysis. Patients with renal AAV who receive transplantation appear to have reduced rates of vasculitis relapse compared with those who remain on dialysis \[[@CR61]\]. However, relapse remains a significant clinical issue in transplant patients and selection of the optimal treatment for maintaining remission is clearly critical. Reintroduction of a cyclophosphamide/high-dose glucocorticoid regimen has shown some success, albeit in a limited number of patients \[[@CR62]\]. The use of rituximab in GPA/MPA patients post-transplantation has not been evaluated extensively, although a number of case reports suggest that rituximab is an effective alternative to standard induction therapy in this situation \[[@CR63], [@CR64]\].

### Pregnancy {#Sec17}

There is no evidence of a teratogenic risk with rituximab. However, given the lack of adequate data on safety on fetal exposure, rituximab is categorized as Category C drug, and effective contraception prior to the first infusion is recommended. In an assessment of the global safety database for rituximab in women who became pregnant, some complications and neonatal abnormalities were reported \[[@CR65]\]. However, these may have been confounded by concomitant use of potentially teratogenic medications and severe underlying disease. Use of rituximab later in pregnancy is associated with B-cell depletion and low IgM levels in the newborn \[[@CR66]\]. In a recent report of 157 women with vasculitis including 22 under the age of 40, 6 patients undergoing treatment with rituximab became pregnant \[[@CR56]\]. There were eight pregnancies in total. One miscarriage occurred at 15 weeks, and the rest of the pregnancies were uneventful. Maternal B cells were depleted at the time of delivery, while B-cell levels were normal in the fetal cord blood. In an individual case, the potential risks of rituximab in pregnancy must be balanced against the benefits of improved disease control and avoidance of other potentially toxic agents. Rituximab is classified by the FDA as a Category C drug with respect to pregnancy.

Rituximab dosing {#Sec18}
----------------

The initial experience with rituximab in severe and refractory GPA/MPA used a regimen of 375 mg/m^2^ once weekly for 4 weeks (4 × 375 mg/m^2^), and this dose and schedule was selected for the prospective RAVE and RITUXVAS trials and is the approved dose in the FDA label. This regimen has been used in most published studies to date, and results in a higher total dose than the standard regimen used in RA (two 1,000-mg infusions separated by 2 weeks). There have not been any dose-ranging studies in vasculitis to determine the optimal protocol, although one retrospective series of 65 patients reported that the 4 × 375 mg/m^2^ and 2 × 1,000-mg regimens induced similar rates of remission (81 and 75 %, respectively) \[[@CR44]\]. Another recent single- center experience with a protocolized treatment of ANCA vasculitis with a single dose of rituximab 375 mg/m^2^ demonstrated that the duration of B-cell depletion was similar to those reported in observational studies and an excellent clinical response with a 3-month probability of complete remission of 80 % and significant cost savings \[[@CR67]\].

Rituximab side effects {#Sec19}
----------------------

As of 2013 more than 220,000 patients have received rituximab for the treatment of RA (Roche/Genentech, data on file). Long-term follow-up data for patients treated with rituximab in RA indicate that it also has a good safety profile \[[@CR68]\]. Nonetheless, rituximab use is associated with specific side effects, some of which can be fatal (these are fully reviewed in the product label \[[@CR69]\]). Infusion-related reactions, most commonly on the initial infusion, can occur, and symptoms of serum-like sickness can develop later. Rituximab is a potent immunosuppressive agent and, as such, increases the risk of infections. However, rates of serious infections in rituximab-treated RA patients were similar to those reported in the general RA population, and there was no increased risk for opportunistic infections \[[@CR68]\]. In the RAVE trial, 10 % of patients suffered serious infections (sepsis or pneumonia). Although there have been reports of use of rituximab for remission-induction in the setting of severe infection, this use is not recommended, and the risks and benefits of such therapy must be weighed carefully \[[@CR70]\]. Late-onset neutropenia has been observed with rituximab, but without increasing the risk of serious infections \[[@CR56], [@CR71]\]. Hypogammaglobulinemia is common during treatment with rituximab \[[@CR60]\]; however, it remains to be fully determined if rituximab-induced hypogammaglobulinemia is associated with an increased risk of infection. Progressive multifocal leukoencephalopathy (PML) has occurred in association with rituximab in other indications \[[@CR72]\], although it is very rare \[\<1 case in 10,000 patient exposures in RA patients treated with rituximab (Roche/Genentech, data on file)\]. Four cases of PML have been reported in patients with GPA in the absence of exposure to rituximab \[[@CR72]\]. As of January 2013, there has been one confirmed case of PML in a 70-year-old breast cancer patient with GPA treated with rituximab and cyclophosphamide (Roche/Genentech, data on file). Rituximab has been reported to reactivate hepatitis B infections at times with severe consequences, and testing patients for HBsAg and anti HB core antibody is recommended. Although data in RA cannot be generalized to GPA/MPA, the long-term experience in rheumatology suggests that rituximab is not associated with an increased malignancy risk.

When is rituximab the first line of therapy in ANCA-associated vasculitis? {#Sec100}
--------------------------------------------------------------------------

Based on available data, rituximab is the first line of therapy for induction of remission in patients who have severe AAV refractory to use of cyclophosphamide. Rituximab is preferred for induction of remission in severe AAV in young patients who wish to preserve fertility. Rituximab is superior to cyclophosphamide in patients with relapsing disease, especially those who are PR3 ANCA positive. However, the utility of rituximab alone in severely ill patients, such as those with renal involvement requiring dialysis at presentation and alveolar hemorrhage requiring mechanical ventilation, needs further study.

Conclusions {#Sec20}
===========

The combination of cyclophosphamide and high-dose glucocorticoids has remained the standard of care approach for remission-induction for the majority of patients with GPA or MPA over four decades. The high rate of remission achieved using this regimen means that it will remain an important therapeutic option. However, some patients fail to achieve remission with cyclophosphamide/glucocorticoid therapy, others suffer relapses during treatment, and there are well-recognized long-term toxicities associated with this regimen. Cyclophosphamide is not FDA approved for the treatment of ANCA-associated vasculitis. The availability of rituximab, which is FDA approved for this indication, now offers an alternative treatment option for the induction of remission in severe GPA/MPA. Rituximab may be considered a first choice therapy for patients with relapsing disease based on the RAVE data, and may be the preferred therapy for remission-induction for some young patients who wish to preserve fertility. The unanswered issues in the role of rituximab as an induction immunosuppressive agent include the use of concomitant cyclophosphamide and adjuvant plasma exchange for patients with life-threatening disease manifestations, and approaches to limit glucocorticoid exposure given the high incidence of AEs. The ongoing MAINRITSAN and RITAZAREM studies should provide a clearer picture of rituximab's safety and efficacy as maintenance therapy in the management of GPA/MPA.
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